Susan Alyson  Wood net worth and biography

Susan Wood Biography and Net Worth

Director of iCAD
Dr. Susan Alyson Wood Ph.D. serves as Independent Director of the Company. She has served as the President and Chief Executive Officer of VIDA Diagnostics, Inc., a leader in precision imaging and AI for pulmonary medicine, since September 2009. From July 2005 to December 2008, she held the position of Executive Vice President of Marketing and Technology for Vital Images, Inc., an innovative software company specializing in cardiovascular applications for advanced analysis software. Dr. Wood holds multiple patents in the field of computer-aided detection and quantitative imaging; has authored numerous book chapters, peer-reviewed papers, abstracts, and has served as an invited speaker at numerous conferences in the area of three-dimensional imaging of the thorax, quantitative imaging and computer-aided detection. She holds a Bachelor of Science in Engineering from the University of Maryland, College Park and a Master of Science in Biomedical Engineering from Duke University. Dr. Wood also holds a Ph.D. from the Johns Hopkins Medical Institutions, School of Hygiene and Public Health.

How do I contact Susan Alyson Wood?

The corporate mailing address for Dr. Wood and other iCAD executives is 98 SPIT BROOK ROAD SUITE 100, NASHUA NH, 03062. iCAD can also be reached via phone at (603) 882-5200 and via email at [email protected]. Learn More on Susan Alyson Wood's contact information.

Has Susan Alyson Wood been buying or selling shares of iCAD?

Susan Alyson Wood has not been actively trading shares of iCAD during the last quarter. Most recently, on Wednesday, December 8th, Susan Alyson Wood bought 1,500 shares of iCAD stock. The stock was acquired at an average cost of $7.31 per share, with a total value of $10,965.00. Learn More on Susan Alyson Wood's trading history.

Who are iCAD's active insiders?

iCAD's insider roster includes Charles Carter (CFO), Jonathan Go (CTO), Timothy Irish (Director), Michael Klein (CEO), Andy Sassine (Director), Stacey Stevens (President), and Susan Wood (Director). Learn More on iCAD's active insiders.

Are insiders buying or selling shares of iCAD?

During the last year, iCAD insiders bought shares 1 times. They purchased a total of 40,000 shares worth more than $52,000.00. The most recent insider tranaction occured on March, 31st when insider Dana R Brown bought 40,000 shares worth more than $52,000.00. Insiders at iCAD own 12.0% of the company. Learn More about insider trades at iCAD.

Information on this page was last updated on 3/31/2023.

Susan Alyson Wood Insider Trading History at iCAD

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/8/2021Buy1,500$7.31$10,965.00View SEC Filing Icon  
See Full Table

Susan Alyson Wood Buying and Selling Activity at iCAD

This chart shows Susan Alyson Wood's buying and selling at iCAD by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

iCAD Company Overview

iCAD logo
iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company's breast AI suite includes cancer detection, automated density assessment, and breast cancer risk assessment solutions for both 2D and 3D mammography. It offers PowerLook, a back-end architecture platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and PowerLook Density Assessment provides automated, consistent, and standardized breast density assessments. The company also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a clinical decision support tool that provides breast cancer risk estimation based on a screening mammogram; and VeraLook, a solution designed to support detection of colonic polyps in conjunction with Computed Tomography Colonography. In addition, it offers Xoft Axxent electronic brachytherapy systems for the treatment of early-stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.
Read More

Today's Range

Now: $1.61
Low: $1.53
High: $1.66

50 Day Range

MA: $1.56
Low: $1.35
High: $2.27

2 Week Range

Now: $1.61
Low: $1.05
High: $3.97

Volume

74,048 shs

Average Volume

198,501 shs

Market Capitalization

$42.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.36